Wall Street analysts expect MAXIMUS, Inc. (NYSE:MMS) to report $760.56 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for MAXIMUS’s earnings, with the highest sales estimate coming in at $772.65 million and the lowest estimate coming in at $752.31 million. MAXIMUS reported sales of $558.45 million in the same quarter last year, which indicates a positive year over year growth rate of 36.2%. The business is scheduled to report its next quarterly earnings results on Tuesday, November 19th.
On average, analysts expect that MAXIMUS will report full-year sales of $2.90 billion for the current fiscal year, with estimates ranging from $2.88 billion to $2.92 billion. For the next fiscal year, analysts forecast that the business will post sales of $3.18 billion, with estimates ranging from $3.13 billion to $3.22 billion. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for MAXIMUS.
MAXIMUS (NYSE:MMS) last released its quarterly earnings results on Thursday, August 8th. The health services provider reported $0.97 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.93 by $0.04. MAXIMUS had a net margin of 8.44% and a return on equity of 20.72%. The company had revenue of $730.70 million for the quarter, compared to analysts’ expectations of $754.81 million. During the same period last year, the company earned $0.91 EPS. The firm’s revenue for the quarter was up 22.2% compared to the same quarter last year.
Several equities research analysts recently issued reports on MMS shares. ValuEngine cut shares of MAXIMUS from a “hold” rating to a “sell” rating in a research report on Monday. Wells Fargo & Co reissued a “market perform” rating and issued a $83.00 target price on shares of MAXIMUS in a research report on Friday, August 9th. Finally, Canaccord Genuity raised their target price on shares of MAXIMUS from $72.00 to $77.00 and gave the stock a “hold” rating in a research report on Tuesday, August 13th.
Shares of MAXIMUS stock traded up $0.76 during mid-day trading on Friday, hitting $74.49. 20,365 shares of the stock were exchanged, compared to its average volume of 364,097. MAXIMUS has a twelve month low of $60.00 and a twelve month high of $82.02. The stock has a market capitalization of $4.73 billion, a price-to-earnings ratio of 22.11, a price-to-earnings-growth ratio of 1.81 and a beta of 0.87. The company has a 50-day simple moving average of $77.49 and a 200 day simple moving average of $74.14.
The firm also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be issued a $0.28 dividend. This is a positive change from MAXIMUS’s previous quarterly dividend of $0.25. The ex-dividend date is Thursday, November 14th. This represents a $1.12 annualized dividend and a yield of 1.50%. MAXIMUS’s dividend payout ratio (DPR) is presently 29.41%.
In related news, General Counsel David Francis sold 6,496 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $77.43, for a total value of $502,985.28. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Russell A. Beliveau sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $77.46, for a total transaction of $77,460.00. The disclosure for this sale can be found here. Insiders sold 55,496 shares of company stock worth $4,398,575 in the last 90 days. 2.20% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of MMS. Advisory Services Network LLC raised its stake in shares of MAXIMUS by 499.0% during the second quarter. Advisory Services Network LLC now owns 593 shares of the health services provider’s stock valued at $43,000 after purchasing an additional 494 shares during the period. Quantamental Technologies LLC purchased a new stake in shares of MAXIMUS during the second quarter valued at approximately $71,000. Signaturefd LLC raised its stake in shares of MAXIMUS by 19.6% during the second quarter. Signaturefd LLC now owns 1,145 shares of the health services provider’s stock valued at $83,000 after purchasing an additional 188 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of MAXIMUS by 70.8% during the second quarter. Tower Research Capital LLC TRC now owns 1,500 shares of the health services provider’s stock valued at $109,000 after purchasing an additional 622 shares during the period. Finally, Marshall Wace North America L.P. purchased a new stake in shares of MAXIMUS during the first quarter valued at approximately $119,000. Hedge funds and other institutional investors own 94.78% of the company’s stock.
MAXIMUS Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services programs worldwide. The company's Health Services segment offers various BPS, appeals, and assessments for state, provincial, and national government programs, including Medicaid, Children's Health Insurance Program, Affordable Care Act, Health Insurance British Columbia, Health Assessment Advisory Service contract, and Preadmission Screening and Resident Reviews.
Further Reading: What is the formula for calculating total return?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.